UPV-EHU ADDI
  • Back
    • English
    • Español
    • Euskera
  • Login
  • English 
    • English
    • Español
    • Euskera
  • FAQ
View Item 
  •   Home
  • INVESTIGACIÓN
  • Artículos, Comunicaciones, Libros
  • Artículos
  • View Item
  •   Home
  • INVESTIGACIÓN
  • Artículos, Comunicaciones, Libros
  • Artículos
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial

Thumbnail
View/Open
1471-2407-13-299.pdf (413.3Kb)
Date
2013-06-19
Author
Solomón, María Teresa
Selva, Julio César
Figueredo, Javier
Vaquer, José
Toledo, Carolina
Quintanal, Nelson
Salva, Silvia
Domínguez, Rafael
Alert, José
Marinello, Jorge Juan
Catalá, Mauricio
González Griego, Martha
Martell, Juan Antonio
Lorenzo Luaces, Patricia
Ballesteros Rodríguez, Francisco Javier
De Castro, Niurys
Bach, Ferdinand
Crombet, Tania
Metadata
Show full item record
BMC Cancer 13(299) : (2013)
URI
http://hdl.handle.net/10810/10404
Abstract
Background The prognosis of patients bearing high grade glioma remains dismal. Epidermal Growth Factor Receptor (EGFR) is well validated as a primary contributor of glioma initiation and progression. Nimotuzumab is a humanized monoclonal antibody that recognizes the EGFR extracellular domain and reaches Central Nervous System tumors, in nonclinical and clinical setting. While it has similar activity when compared to other anti-EGFR antibodies, it does not induce skin toxicity or hypomagnesemia. Methods A randomized, double blind, multicentric clinical trial was conducted in high grade glioma patients (41 anaplastic astrocytoma and 29 glioblastoma multiforme) that received radiotherapy plus nimotuzumab or placebo. Treatment and placebo groups were well-balanced for the most important prognostic variables. Patients received 6 weekly doses of 200 mg nimotuzumab or placebo together with irradiation as induction therapy. Maintenance treatment was given for 1 year with subsequent doses administered every 3 weeks. The objectives of this study were to assess the comparative overall survival, progression free survival, response rate, immunogenicity and safety. Results The median cumulative dose was 3200 mg of nimotuzumab given over a median number of 16 doses. The combination of nimotuzumab and RT was well-tolerated. The most prevalent related adverse reactions included nausea, fever, tremors, anorexia and hepatic test alteration. No anti-idiotypic response was detected, confirming the antibody low immunogenicity. The mean and median survival time for subjects treated with nimotuzumab was 31.06 and 17.76 vs. 21.07 and 12.63 months for the control group. Conclusions In this randomized trial, nimotuzumab showed an excellent safety profile and significant survival benefit in combination with irradiation.
Collections
  • Artículos

DSpace software copyright © 2002-2015  DuraSpace
OpenAIRE
OpenAIRE
 

 

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesDepartamentos (cas.)Departamentos (eus.)SubjectsThis CollectionBy Issue DateAuthorsTitlesDepartamentos (cas.)Departamentos (eus.)Subjects

My Account

Login

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
OpenAIRE
OpenAIRE